Gilead Sciences, Inc. 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 4:42 pm Purchase | 2025-06-30 | 13G | Xilio Therapeutics, Inc. XLO | GILEAD SCIENCES INC. GILD | 10,613,944 19.900% | 1,508,493 (+16.57%) | Filing |
| 2024-12-19 4:15 pm Purchase | 2024-12-18 | 13G | Xilio Therapeutics, Inc. XLO | GILEAD SCIENCES INC. GILD | 9,105,451 19.900% | 1,759,978 (+23.96%) | Filing |
| 2024-04-05 4:31 pm Purchase | 2024-03-27 | 13G | Xilio Therapeutics, Inc. XLO | GILEAD SCIENCES INC. GILD | 7,345,473 19.900% | 7,345,473 (New Position) | Filing |